fbpx

Pilot Hemostatic Performance of MIRRAGEN

Collaboration with OHSU, Dr. Schreiber, Chief, Division of Trauma,
Critical Care and Acute Care Surgery
Objective: Utilize the Thrombelastograph (TEG) to examine the hemostatic properties of each test agent in vitro.
  • MIRRAGEN(formerly known as DermaFuse)
  • Whole Blood
  • Combat Gauze
  • Kerlix

Dr. Schreiber

Chief, Division of Trauma, Critical Care and Acute Care Surgery

(OHSU)
Pilot Hemostatic Performance of MIRRAGEN

Hemostatic Performance of MIRRAGEN

Reactiontime, Minutes Time For Initial Fibrin
Clot Formation

Maximum Amplitude (Millimeters)
Maximum Clot Strength or Firmness


Percent Lysis at 30 min
Post MaxClot Strength

Coagulation Index, CI
Overall Coagulation

  • Reaction time; R, min — the time that the initial fibrin formation is detected
  • Clotting time; K, min — the speed of clot formation and is the time from the R time until a clot with a fixed firmness is formed
  • Angle; a, degree — the kinetics of clot development
  • Maximum amplitude; MA, mm — the maximum strength or firmness of the developed clot
  • Coagulation index; CI — overall coagulation
  • LY30 — percent lysis at 30 min post maximum clot strength
Pilot Study performed® OHSU, Division of Trauma and Acute Care Surgery n=2/group
Hemostatic Performance of MIRRAGEN

Antibacterial Testing of MIRRAGEN

Preliminary USP 51
OrganismLog Reduction
A. brasiliensis (ATCC 16404)
6.04
E. coli (ATCC 8739)
5.93
C. albicans (ATCC 10231)
5.91
P. aeruginosa (ATCC 9027)
6.08
S. aureus (ATCC 6538)
5.5

Extraordinary Results: > 5.5 Log Reduction within 14 days
Antibacterial Testing of MIRRAGEN

Table 8.3 Log10 Reduction of Recovered Micro-organisms

Report 18-0590-1088
*Cells Highlighted in Red indicate >4-Log10 (99.99%) reduction in recovered bacteria
Table 8.3 Log10 Reduction of Recovered Micro-organisms

Table 8.4 % Killing of Recovered Micro-organisms

Report 18-0590-1088
Table 8.4 % Killing of Recovered Micro-organisms